naloxone by removing current policies and laws that act as barriers.
The authors also mentioned efforts by the U.S. Food and Drug Administration — the Opioids Action Plan of 2016 asked the National Academies of Sciences, Engineering, and Medicine to assemble a committee to report on the ongoing science on pain research, care and the identification of proper reactions the FDA and communities can take in response to the opioid crisis.
The study provided a few conclusions: access to OUD treatment based on research and evidence must be immediately and substantially expanded as a public health priority; public health and political leadership is necessary to decrease new cases of opioid addiction; and scientifically sound policies and clinical disciplines toward accountable opioid prescribing are as fundamental as ongoing research to create non-addictive options to pain treatment.
